Romani L, Puccetti P, Fioretti M C, Mage M G
Int J Cancer. 1985 Aug 15;36(2):225-31. doi: 10.1002/ijc.2910360215.
Treatment of murine lymphomas with triazene derivatives may lead to the appearance of novel drug-mediated tumor antigens, a phenomenon known as chemical xenogenization. Such antigens, which are capable of eliciting specific transplantation resistance in histocompatible mice, have been previously detected by in vivo and in vitro cell-mediated immune responses. In the present report we address the question of the humoral antibody response to a chemically xenogenized lymphoma. Histocompatible mice were given several injections of live cells of the xenogenized tumor. Ten days after each immunization, pooled sera from different animals were analyzed for Ab content by means of flow microfluorometry analysis and CEL-ISA assay. The results reveal that antibodies of both IgG and IgM classes capable of binding the xenogenized tumor can already be detected after one single sensitization. However, the Ab titer gradually increases through subsequent immunizations, reaching a peak level after 3-4 injections at a time when most of the humoral response is made up of antibodies of IgG class. The specificity of the anti-xenogenized tumor hyperimmune sera was subsequently investigated by its reaction with the parental, non-xenogenized line and with normal tissue cells of the same or allogeneic haplotypes. The data obtained point out that cross-reactivity with the parental line could be completely removed by absorption of the hyperimmune sera on parental cells, which removed most of the IgM antibodies. Moreover, the presence of an excess of anti-parental antibodies on the xenogenized tumor cells does not prevent the subsequent binding of the hyperimmune absorbed serum, thus indicating that the novel determinant(s) recognized on xenogenized cells are not spatially related to those shared with the original parental tumor. In addition, the hyperimmune absorbed serum does not cross-react with normal hemopoietic or lymphoid cells of the same (H-2d) or allogeneic H-2b and H-2k haplotypes. Furthermore, no alien histocompatibility antigens of H-2b or H-2k haplotypes could be detected on the xenogenized tumor cell surface. Taken together, these data provide evidence that chemical xenogenization of a murine lymphoma leads to the appearance of novel determinant(s) detectable by specific antibodies.
用三氮烯衍生物治疗小鼠淋巴瘤可能会导致出现新的药物介导的肿瘤抗原,这一现象被称为化学异种源化。这种能够在组织相容性小鼠中引发特异性移植抗性的抗原,此前已通过体内和体外细胞介导的免疫反应检测到。在本报告中,我们探讨了对化学异种源化淋巴瘤的体液抗体反应问题。给组织相容性小鼠多次注射异种源化肿瘤的活细胞。每次免疫后10天,通过流式微荧光分析和CEL-ISA测定法分析来自不同动物的混合血清中的抗体含量。结果显示,单次致敏后就能检测到能够结合异种源化肿瘤的IgG和IgM类抗体。然而,抗体滴度在随后的免疫过程中逐渐升高,在3 - 4次注射后达到峰值水平,此时大部分体液反应由IgG类抗体组成。随后通过抗异种源化肿瘤超免疫血清与亲代、未异种源化细胞系以及相同或同种异体单倍型的正常组织细胞的反应来研究其特异性。获得的数据表明,通过用亲代细胞吸收超免疫血清可以完全消除与亲代细胞系的交叉反应,这消除了大部分IgM抗体。此外,异种源化肿瘤细胞上存在过量的抗亲代抗体并不妨碍随后超免疫吸收血清的结合,因此表明在异种源化细胞上识别的新决定簇在空间上与原始亲代肿瘤共有的决定簇无关。此外,超免疫吸收血清与相同(H-2d)或同种异体H-2b和H-2k单倍型的正常造血或淋巴细胞不发生交叉反应。此外,在异种源化肿瘤细胞表面未检测到H-2b或H-2k单倍型的外来组织相容性抗原。综上所述,这些数据提供了证据,表明小鼠淋巴瘤的化学异种源化导致出现可被特异性抗体检测到的新决定簇。